Neurocrine drops MS agent
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Neurocrine Biosciences discontinues NBI-5788 compound development for multiple sclerosis following the altered peptide ligand (APL) product's Phase II failure, the firm announces March 8. "The company will complete its other APL Phase II study, which is evaluating the APL technology for the treatment of type 1 diabetes, which is utilizing a different APL epitope," Neurocrine says. The Phase II MS trial failed to show statistical significance in 157 subjects over a nine-month period….